Form 8-K Anika Therapeutics, Inc. For: Feb 21
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Sidoti Downgrades Anika Therapeutics (ANIK) to Neutral
February 22, 2019 8:48 AM ESTSidoti analyst James Sidoti downgraded Anika Therapeutics (NASDAQ: ANIK) from Buy to Neutral with a price target of $41.00 (from $56.00).
The analyst cited uncertainty regarding CINGAL approval.
For an analyst ratings summary and ratings history on Anika Therapeutics... More
